Your trusted source for investing success
In case you missed it, here is this week’s cannabis big news roundup.
In case you missed it, here is this week’s big news roundup in the Life Science sector.
This is the archive of cannabis big news roundups
RISE Life Science Corp. (CSE:RLSC) (formerly Luminor Medical Technologies Inc.) (the “Company”) announces that it intends to complete a non-brokered private placement of up to 10,000,000 units (“Units”) at a price of $0.30 per Unit (the “Issue Price”) for gross proceeds of up to $3,000,000 (the “Offering”).
RISE Life Science Corp. (CSE:LMT) (formerly Luminor Medical Technologies Inc.) (the “Company”) is pleased to announce that at the opening of the market on Wednesday March 14, 2018, the Company will begin trading on the Canadian Securities Exchange “CSE” under its new stock symbol: RLSC.
Luminor Medical Technologies (TSXV:LMT), further to the acquisition of RISE Research Inc., announced today that it changed its corporate name to RISE Life Science Corp. which was approved at the Company’s annual and special shareholder meeting (the “Shareholder Meeting”) held on Tuesday February 27, 2018.
Luminor Medical Technologies (TSXV:LMT) recently got featured on CFN Media regarding the company’s partnership with Constance Therapeutics.
The companies have agreed to develop and market cannabis-based sexual health products, a large and growing market, starting this year in California.
The article describes the California Cannabis market as an extremely profitable one with revenue that
Luminor Medical Technologies (TSXV:LMT) recently got featured in CFN Media in regards to it’s interest in the “burgeoning” California Cannabis Industry.
Luminor Medical Technologies Inc. (“the Company”) (CSE: LMT) is pleased to announce it has completed the acquisition of RISE Research Inc. (“RISE Research”), and at its Annual General Meeting to be held on February 27, 2018 the Company plans to change its name to RISE Life Science Corp.
RISE Research Inc. (“RISE”) and Luminor Medical Technologies Inc. (TSXV:LMT) (“Luminor”) are pleased to announce RISE’s comprehensive strategic partnership with Constance Therapeutics (“CT”), an established San Francisco-based developer and manufacturer of premium medical cannabis extract products for physician and patient use in California.
Luminor Medical Technologies Inc. (CSE: LMT) (“the Company”) is pleased to announce it has executed an agreement (the “Agreement”) to acquire 100% of the issued and outstanding shares of RISE Research Inc. (“RISE”, “RISE Research”).
Luminor Medical Technologies (TSXV:LMT) recently announced that it has started trading on the Canadian Securities Exchange.
By Micha Boon
Luminor Medical Technologies Inc. (the “Company”) (TSXV:LMT) (CSE:LMT) announced today that the Canadian Securities Exchange (CSE) has approved the Company’s application to list its common shares on the CSE. Effective December 1, 2017, the Company’s shares will commence trading on the CSE under the symbol LMT. The Company has also applied
By Shelly Kumar
Luminor Medical Technologies (TSXV:LMT) announces that further to its news release dated September 12, 2017, the Company has closed its acquisition of Jamaica-Blu Ltd. (“J-BLU”). J-BLU holds the exclusive Canadian licence of all current and future cannabis commercial products developed by Rise Research Inc. (“RISE”). RISE’s cannabis commercial products are based on
By Shelly Kumar
Luminor Medical Technologies (TSXV:LMT) is pleased to announce that it has amended the terms of its acquisition of Jamaica-BLU Ltd. (“J-BLU”) which was previously announced on May 10, 2017 and that it plans to close up to $3,000,000 in a private placement financing (the “Financing”) at a price of $0.15 per
By Pia Rivera
Here at the Investing News Network our mission is twofold; to provide the latest news and quality education by helping you identify investment opportunities in niche markets, and helping leading companies communicate their value to investors.
By Shelly Kumar
Luminor Medical Technologies Inc. (TSXV:LMT) (the “Company” or “Luminor Medical”) (formerly Miraculins Inc.) is pleased to announce that it has executed a letter of intent (the “LOI”) to acquire the exclusive Canadian and Jamaican licences for all current and future cannabis commercial products (the “Acquisition”) owned by Jamaica BLU Ltd.
Luminor Medical Technologies (TSXV:LMT) (formerly Miraculins Inc.), announces today that it has appointed Dr. Edward Hillhouse as Chairman of the Luminor Medical Scientific Advisory Board.
By Shelly Kumar
Luminor Medical Technologies Inc. (TSXV:LMT) CEO Christian Sauvageau tells investors the 3 things everyone should know about the company, as well as the one unique factor that distinguishes it from competitors in the medical device industry.
Should you decide that the TSXV is right for you, the Investing News Network has compiled a list of some medical device, genetics, pharmaceutical and biotech stocks currently trading on this exchange—as well as their area of focus.
